Literature DB >> 11229272

Tuberculosis in patients with systemic lupus erythematosus.

C Balakrishnan1, G Mangat, G Mittal, V R Joshi.   

Abstract

In a retrospective analysis of 146 systemic lupus erythematosus (SLE) patients seen over a 5 year period, 17 patients of tuberculosis (TB) were identified yielding a prevalence rate of 11.6%. The median duration of SLE was 12 months (range 2-96 months) and 12/17 patients had disease activity score of more than five. The median duration of steroid treatment was 12 months (range 0-96 months) and the median cummulative dose of steroid was 7.75 gms (range 0-22.1 gms). Pulmonary TB (miliary-5, nonmiliary infiltrates-7 and pleural effusion-2) was the commonest type and there was an average diagnostic delay of approximately 1 month. While, majority of the patients responded adequately to treatment, 1 patient had a relapse and 1 expired due to a combination of active lupus and disseminated TB. Only 1 patient had received prophylactic isoniazid.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 11229272

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  11 in total

1.  Prophylactic use of antibiotics and immunisations in patients with SLE.

Authors:  W R Gilliland; G C Tsokos
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

2.  Factors associated with active tuberculosis in Colombian patients with systemic lupus erythematosus: a case-control study.

Authors:  Luis Alonso González-Naranjo; Jaime Alberto Coral-Enríquez; Mauricio Restrepo-Escobar; Carlos Horacio Muñoz-Vahos; Daniel Jaramillo-Arroyave; Adriana Lucía Vanegas-García; Ruth Eraso; Gloria Vásquez; Fabián Jaimes
Journal:  Clin Rheumatol       Date:  2020-06-11       Impact factor: 2.980

3.  The risk of tuberculosis in SLE patients from an Asian tertiary hospital.

Authors:  Yong Yang; Julian Thumboo; Ban Hock Tan; Thuan Tong Tan; Chern Hui Jeffrey Fong; Han Seong Ng; Kok Yong Fong
Journal:  Rheumatol Int       Date:  2017-03-12       Impact factor: 2.631

4.  Tuberculosis and systemic lupus erythematosus: a case-control study in Mexico City.

Authors:  Pedro Torres-González; Juanita Romero-Díaz; Miguel Enrique Cervera-Hernández; Mario Ocampo-Torres; Luis Gerardo Chaires-Garza; Ernesto Alejandro Lastiri-González; Yemil Atisha-Fregoso; Miriam Bobadilla-Del-Valle; Alfredo Ponce-de-León; José Sifuentes-Osornio
Journal:  Clin Rheumatol       Date:  2018-04-20       Impact factor: 2.980

5.  Tuberculosis infection in patients with systemic lupus erythematosus: pulmonary and extra-pulmonary infection compared.

Authors:  Chih-Lung Hou; Yi-Chan Tsai; Li-Chen Chen; Jing-Long Huang
Journal:  Clin Rheumatol       Date:  2007-10-17       Impact factor: 2.980

6.  Mycobacterium tuberculosis infection precipitates SLE in patients from endemic areas.

Authors:  Kanjaksha Ghosh; Manisha Patwardhan; Vandana Pradhan
Journal:  Rheumatol Int       Date:  2009-04-10       Impact factor: 2.631

7.  Can lupus flares be associated with tuberculosis infection?

Authors:  F M Ribeiro; M Szyper-Kravitz; E M Klumb; G Lannes; F R E Ribeiro; E M M Albuquerque; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

8.  Exacerbation of latent lupus: is the culprit acid-fast bacilli or antitubercular therapy?

Authors:  Harpreet Singh; Sucharita Ray; Maneet Kaur; Vikas Gupta; Harish Kumar; Paulomi Talapatra; Rekha Mathur; Suvrat Arya; Naveen Ghangas
Journal:  Clin Rheumatol       Date:  2013-04-10       Impact factor: 2.980

Review 9.  SLE and infections.

Authors:  Gisele Zandman-Goddard; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

10.  Miliary Tuberculosis Presenting With Meningitis in a Patient Treated With Mycophenolate for Lupus Nephritis: Challenges in Diagnosis and Review of the Literature.

Authors:  Precious Macauley; Mark Rapp; Sarah Park; Olaoluwatomi Lamikanra; Pratibha Sharma; Michael Marcelin; Kavita Sharma
Journal:  J Investig Med High Impact Case Rep       Date:  2018-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.